WFH news
-
Alnylam Suspends Fitusiran Dosing due to Thrombotic Event in Phase 2 open-label extension study
The WFH was saddened to learn of the death of a hemophilia A patient taking part in the Phase II trial of fitusiran, in development...
-
2017 Clinical Research Grant recipients announced
The WFH is happy to announce the 2017 Clinical Research Grant recipients. Research grants are awarded to outstanding international investigators conducting important clinical and diagnostic research with global...
-
WFH supports capacity-building initiative in southeast Asia
Patient organization leaders gathered during the Association of Southeast Asian Nations (ASEAN) Hemophilia Network Workshop in May, taking part in trainings to help improve hemophilia...
-
2016 Twins of the Year help make a difference
The WFH Hemophilia Treatment Centre (HTC) 2016 Twins of the Year have made a significant improvement in the care and diagnosis of people in the...
-
WFH signs Memorandum of Understanding with newly formed Coalition of the Americas ensuring program development and collaboration within the region
Strengthening the regional presence of the World Federation of Hemophilia (WFH) is one of the organization’s priorities. As the mission of the WFH outlines, together...
